- Posted April 08, 2014
- Tweet This | Share on Facebook
Supreme Court takes up drug company dispute
WASHINGTON (AP) -- The Supreme Court is wading into a patent dispute between rival pharmaceutical companies over a multiple sclerosis treatment.
The justices agreed last week to hear an appeal from Teva Pharmaceutical Industries Ltd., which claims the U.S. Court of Appeals for the Federal Circuit wrongly overturned five of its patents for the drug Copaxone.
The appeals court ruling would allow rivals Mylan Inc., Momenta Pharmaceuticals Inc. and Sandoz, Inc., to start selling generic versions of the drug later this year, after the remaining patents on the drug expire.
A federal district court had earlier ruled in Teva's favor and upheld the patents. Teva says the federal circuit should have deferred to factual findings made in the district court.
The justices will hear the case in the fall.
Published: Tue, Apr 8, 2014
headlines Oakland County
- Judge’s memorial unveiled
- Judge to lead community-based behavioral health workshop
- ABA President Michelle A. Behnke calls Equity Summit 2026 ‘a step towards action’
- Michigan Human Trafficking Commission launches quarterly newsletter
- Nessel files testimony to protect ratepayers in Google data center proposal
headlines National
- Bill Kurtis’ memoir tells how law school trained him for covering trials
- ACLU and BigLaw firm use ‘Orange is the New Black’ in hashtag effort to promote NY jail reform
- Justice Barrett’s home targeted in attempted swatting call
- Texting-and-driving charges dropped against woman without right hand
- Fender warns guitar makers to stop producing Stratocaster look-a-likes
- General counsel compensation climbs, aligned with equity and company scale




